Insulin Aspart

證據等級: L5

預測適應症: 10 個

Insulin Aspart: Established Rapid-Acting Insulin Analogue for Type 1 Diabetes Mellitus — Not Currently Registered with SAHPRA

One-Sentence Summary

Insulin aspart (NovoRapid®/NovoLog®) is a rapid-acting human insulin analogue used globally as the cornerstone bolus insulin for postprandial glucose control in both type 1 and type 2 diabetes mellitus. The TxGNN model predicts it as highly effective for Type 1 Diabetes Mellitus (T1DM) with a score of 99.95% — this reflects the drug’s well-established primary indication globally rather than a novel repurposing opportunity. Importantly, insulin aspart currently carries no SAHPRA registration in South Africa, despite being supported by multiple completed Phase 3 RCTs across international populations and an L1 evidence level.

Quick Overview

Item	Content
Original Indication	Not registered with SAHPRA (globally approved for T1DM and T2DM as bolus insulin)
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.95%
Evidence Level	L1
South Africa Market Status	Not registered
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Clinical Note: This TxGNN prediction does not represent a novel repurposing scenario. Insulin aspart is the globally established standard of care for T1DM and is listed on the WHO Model Essential Medicines List. The TxGNN model’s high-confidence identification of T1DM confirms model accuracy rather than uncovering a new indication. The practical significance of this report for South African healthcare professionals lies in the current absence of SAHPRA registration, not in unproven efficacy.

Insulin aspart is a structurally modified human insulin analogue in which the amino acid proline at position B28 of the insulin B-chain has been substituted with aspartic acid. This single amino acid substitution reduces the tendency for self-aggregation at the injection site, resulting in faster subcutaneous absorption. Peak serum insulin concentrations are reached within 40–50 minutes of subcutaneous injection (compared to 80–120 minutes for regular human insulin), enabling more physiological coverage of postprandial glucose excursions.

Type 1 Diabetes Mellitus is characterised by autoimmune destruction of pancreatic β-cells, leading to absolute insulin deficiency. Exogenous insulin replacement is not merely beneficial — it is life-sustaining. Insulin aspart directly addresses this deficiency by providing rapid-onset, short-duration bolus insulin to match carbohydrate intake at mealtimes. This mechanistic link is direct and unambiguous, forming the pharmacological foundation for regulatory approvals by the EMA, US FDA, and numerous other agencies worldwide.

The TxGNN knowledge graph captures the dense network of clinical trial data, published literature, and biological pathway evidence connecting insulin aspart to T1DM — reflected in the near-perfect prediction score of 99.95%. This is entirely consistent with decades of clinical use. However, the lack of SAHPRA registration means South African patients with T1DM currently have no straightforward regulatory pathway to access this medicine domestically.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01848990	Phase 4	Completed	456	CONSISTENT 1: Large RCT in T1DM evaluating hyaluronidase preadministration with insulin aspart CSII — compared HbA1c change at 6 months and rates of hypo- and hyperglycaemia vs standard CSII
NCT01445951	Phase 3	Completed	518	Forced-titration RCT comparing inhaled Technosphere insulin to insulin aspart (both combined with basal insulin) in T1DM over 24 weeks — directly evaluated insulin aspart efficacy and safety
NCT03760068	Phase 3	Completed	478	Multicentre open-label RCT demonstrating equivalence in safety and efficacy between biosimilar MYL-1601D and reference NovoLog® (insulin aspart) in T1DM patients
NCT01835431	Phase 3	Completed	362	Insulin degludec/aspart once daily + insulin aspart for remaining meals vs insulin detemir + insulin aspart in children and adolescents with T1DM — conducted across Asia, Europe, and the Americas
NCT00978627	Phase 3	Completed	548	BOOST T1: IDegAsp once daily + insulin aspart vs insulin detemir + insulin aspart in adults with T1DM — main 26-week period plus long-term extension
NCT00184665	Phase 3	Completed	501	Insulin detemir vs NPH insulin, both with insulin aspart bolus, in T1DM — conducted across Africa, Asia, Europe, Oceania, and South America; assessed HbA1c reduction, hypoglycaemia frequency, and body weight
NCT04079413	Phase 3	Completed	264	Open-label multicentre RCT comparing biosimilar GP40071 (insulin aspart, GEROPHARM) vs NovoRapid® in T1DM — parallel-group efficacy and safety comparison
NCT02855307	Phase 2	Completed	37	Crossover RCT assessing single-hormone closed-loop strategy with insulin aspart in adults with T1DM — evaluated prevention of exercise-induced hypoglycaemia during announced and unannounced physical activity
NCT00365170	Phase 4	Completed	419	Insulin aspart vs human insulin (Actrapid®) in pregnant women with T1DM on multiple daily injections — compared maternal hypoglycaemia rates and perinatal outcomes across Europe, Middle East, and the Americas
NCT00472953	Phase 3	Terminated	38	Inhaled human insulin vs subcutaneous insulin aspart in T1DM/T2DM patients with comorbid COPD — terminated early due to low enrolment; insulin aspart served as active comparator

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37863084	2023	RCT	Lancet	ONWARDS 6: Once-weekly insulin icodec vs once-daily insulin degludec as basal component in T1DM adults — insulin aspart used as the bolus throughout; establishes contemporary T1DM basal-bolus context
36623517	2023	RCT	Lancet Diabetes & Endocrinology	EXPECT trial: Non-inferiority RCT of insulin degludec vs insulin detemir, both combined with insulin aspart, in pregnant women with T1DM — assessed efficacy and safety during gestation
37804858	2023	RCT	Lancet Diabetes & Endocrinology	CopenFast: Faster-acting insulin aspart vs insulin aspart in T1DM/T2DM during pregnancy and post-delivery — evaluated fetal growth and glycaemic control; insulin aspart confirmed safe in obstetric setting
40129237	2025	RCT	Diabetes, Obesity & Metabolism	Double-blind crossover RCT comparing faster-acting insulin aspart vs insulin aspart in T1DM adults using non-automated insulin pump combined with CGM — evaluated time in range and hypoglycaemia
21333580	2011	Systematic Review	Diabetes & Metabolism	Systematic review of insulin aspart vs regular human insulin, and biphasic aspart vs premixed human insulin, in T1DM and T2DM — demonstrated superior postprandial control and non-inferior or better HbA1c with insulin aspart
38379002	2024	PK/PD Study	Diabetes, Obesity & Metabolism	PK/PD characterisation of once-weekly insulin icodec using insulin aspart as bolus comparator in T1DM individuals — provides contemporary pharmacological benchmarking data
31902063	2020	Review	Diabetes Therapy	Narrative review of insulin management strategies in non-pregnant adults with T1DM — covers MDI with rapid-acting analogues, CSII, closed-loop systems, and role of insulin aspart in each modality
37290466	2023	Review	Lancet Diabetes & Endocrinology	Comprehensive review of T1DM management in pregnancy — highlights insulin aspart as preferred bolus insulin with diabetes technology (CGM, pumps, hybrid closed-loop) to achieve time-in-range targets
15871555	2003	Review	Treatments in Endocrinology	Early landmark review of insulin aspart in T1DM and T2DM — demonstrated significantly lower HbA1c and improved postprandial glucose control vs regular human insulin across randomised trials
12215068	2002	Review	Drugs	Comprehensive review establishing insulin aspart’s pharmacokinetic advantages over regular human insulin and its clinical efficacy and safety profile in T1DM and T2DM

South Africa Market Information

Insulin aspart currently has no SAHPRA registration. There are no approved product licences on the South African market at this time.

Healthcare professionals requiring access to insulin aspart in South Africa should note the following regulatory pathways:

Section 21 Authorisation: SAHPRA may grant approval for unregistered medicines on a named-patient or cohort basis where clinical need is demonstrated and no equivalent registered alternative is available.
Parallel importation: Refer to SAHPRA guidelines on importing medicines registered by recognised regulatory authorities (e.g., EMA, US FDA).
Current domestic alternatives: Healthcare professionals should consult the South African Essential Medicines List (EML) for currently registered rapid-acting insulin options available through public sector supply chains.

Safety Considerations

Please refer to the manufacturer’s approved Professional Information (PI) — such as the EMA-approved NovoRapid® Summary of Product Characteristics or the US FDA-approved NovoLog® Prescribing Information — for complete safety data, as insulin aspart is not currently registered with SAHPRA. Report any adverse drug reactions to SAHPRA via the MedSafety pharmacovigilance reporting system.

For reference, insulin aspart is a well-characterised medicine with decades of post-marketing safety data. International regulatory databases consistently identify hypoglycaemia as the most clinically significant risk, with dose-related frequency. Injection site reactions, lipohypertrophy (with repeated injection at the same site), and insulin antibody formation are also documented. Special populations requiring careful monitoring include pregnant women, children, elderly patients, and those with renal or hepatic impairment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Insulin aspart is an L1-evidence, globally-approved, WHO-listed essential medicine for Type 1 Diabetes Mellitus, confirmed by multiple completed Phase 3 RCTs including trials conducted on the African continent. The absence of SAHPRA registration — not lack of efficacy or safety data — is the sole barrier to routine clinical use in South Africa.

To proceed, the following is needed:

Regulatory: Submit or support a SAHPRA registration dossier for insulin aspart, or initiate Section 21 applications for named-patient access in cases of clinical urgency
EML Review: Assess whether insulin aspart should be added to the South African National Essential Medicines List alongside or in place of currently listed rapid-acting insulins
Pharmacoeconomics: Conduct a cost-effectiveness analysis comparing insulin aspart to currently registered rapid-acting insulins (e.g., regular human insulin) in the South African healthcare context, including public sector affordability
Cold chain logistics: Verify cold-chain distribution capacity across South African provinces for insulin analogue storage and delivery
Safety PI: Obtain and localise the full Professional Information document from EMA/FDA-approved labelling pending SAHPRA registration
MOA data: Retrieve full mechanism-of-action details from DrugBank (DB01306) to complete pharmacological profiling for the regulatory dossier

This report is generated for research and regulatory planning purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Healthcare professionals should refer to SAHPRA-approved prescribing information and report adverse drug reactions to SAHPRA.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.